FDA approves Vyvanse to treat binge eating disorder in adults

The FDA has approved Vyvanse (lisdexamfetamine) to treat moderate to severe binge eating disorder (BED) in adults. Vyvanse is a central nervous system stimulant that was already approved for attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 and older. This new approval provides a medication option for people with BED, a condition where a person has repeated episodes of eating large amounts of food and feels a loss of control during the binge. It is important to know that Vyvanse is not approved for weight loss, and its safety and effectiveness for weight loss or obesity have not been studied. The recommended starting dose for BED is 30 mg once daily, with the dose increased weekly to a target of 50 to 70 mg daily. If binge eating does not improve, treatment should be stopped. If you or someone you know has binge eating disorder, talk to a doctor about whether Vyvanse might be a helpful option. This approval gives patients a new choice, but it is not a quick fix. Always discuss the risks and benefits with your healthcare provider.